Ecogen, Monsanto, 3A S.r.l. deal

The companies signed a letter of intent to develop EECN's Bacillus thuringiensis (Bt) technology for in-plant applications. Monsanto will acquire rights to EECN's library of more than 10,000 Bt strains and will have exclusive worldwide rights to develop the Bt genes for in-plant technology. EECN will retain exclusive rights for Bt development in all other areas and will have unrestricted rights to technology developed under the Monsanto agreement for non-plant use.

EECN, which closed at $1.75 on Friday, has 28.8 million shares outstanding prior to the investment. ...